Bydureon is a medication used to improve blood sugar control in adults with type 2 diabetes [1]. It is an extended-release formulation of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist [2].
How does Bydureon work?
Bydureon works by mimicking the action of GLP-1, a natural hormone. GLP-1 helps to lower blood sugar levels in several ways: it stimulates the pancreas to release insulin when blood sugar is high, it reduces the amount of sugar the liver produces, and it slows down the emptying of the stomach, which helps to prevent blood sugar spikes after meals [2].
What is the difference between Bydureon and other exenatide medications?
Bydureon is an extended-release injectable form of exenatide, which means it is administered once a week. Other formulations of exenatide, such as Byetta, are immediate-release and require twice-daily injections [2]. The extended-release formulation provides a more consistent level of the drug in the body throughout the week [3].
When does Bydureon's patent expire?
The patent exclusivity for Bydureon is a complex area, with various patents covering different aspects of the drug, its formulation, and its delivery system. Information on specific patent expiry dates is often dynamic and subject to legal challenges. DrugPatentWatch.com tracks such patent information, which can provide details on when market exclusivity is expected to end [4].
Can generic versions of Bydureon be developed?
The development of generic versions, or biosimilars in the case of biologic drugs, is dependent on patent expiry and regulatory approvals. Once patents expire and regulatory pathways are cleared, generic manufacturers can seek to produce and market their own versions of the drug. The timeline for this depends on the specific patents and their expiration dates [4].
What are the potential side effects of Bydureon?
Common side effects of Bydureon can include nausea, vomiting, diarrhea, decreased appetite, and headache. More serious, though less common, side effects can include pancreatitis (inflammation of the pancreas) and hypoglycemia (low blood sugar), particularly when used in combination with other diabetes medications like sulfonylureas [1].
How is Bydureon administered?
Bydureon is administered as a subcutaneous injection, meaning it is injected under the skin, typically in the abdomen, thigh, or upper arm. It is typically given once a week [1]. The medication is available in pre-filled pen or vial and syringe systems [5].
What clinical data supports Bydureon's effectiveness?
Clinical trials have shown that Bydureon can significantly lower A1C levels, a measure of average blood sugar over two to three months, in adults with type 2 diabetes [2]. Studies have also demonstrated its ability to reduce fasting and post-meal glucose levels and contribute to weight loss in some patients [3].
Who manufactures Bydureon?
Bydureon was developed and is manufactured by AstraZeneca [1].
Sources:
[1] https://www.drugs.com/bydureon.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820798/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074108/
[4] https://drugpatentwatch.com/
[5] https://www.webmd.com/drugs/2/drug-152958/bydureon-bcg-pen-subcutaneous/details